Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity.

Vincent BM, Tardiff DF, Piotrowski JS, Aron R, Lucas MC, Chung CY, Bacherman H, Chen Y, Pires M, Subramaniam R, Doshi DB, Sadlish H, Raja WK, Solís EJ, Khurana V, Le Bourdonnec B, Scannevin RH, Rhodes KJ.

Cell Rep. 2018 Dec 4;25(10):2742-2754.e31. doi: 10.1016/j.celrep.2018.11.028.

2.

Potent PDZ-Domain PICK1 Inhibitors that Modulate Amyloid Beta-Mediated Synaptic Dysfunction.

Lin EYS, Silvian LF, Marcotte DJ, Banos CC, Jow F, Chan TR, Arduini RM, Qian F, Baker DP, Bergeron C, Hession CA, Huganir RL, Borenstein CF, Enyedy I, Zou J, Rohde E, Wittmann M, Kumaravel G, Rhodes KJ, Scannevin RH, Dunah AW, Guckian KM.

Sci Rep. 2018 Sep 7;8(1):13438. doi: 10.1038/s41598-018-31680-3.

3.

Therapeutic strategies for targeting neurodegenerative protein misfolding disorders.

Scannevin RH.

Curr Opin Chem Biol. 2018 Jun;44:66-74. doi: 10.1016/j.cbpa.2018.05.018. Epub 2018 Jun 11. Review.

PMID:
29902695
4.

Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.

Scannevin RH, Alexander R, Haarlander TM, Burke SL, Singer M, Huo C, Zhang YM, Maguire D, Spurlino J, Deckman I, Carroll KI, Lewandowski F, Devine E, Dzordzorme K, Tounge B, Milligan C, Bayoumy S, Williams R, Schalk-Hihi C, Leonard K, Jackson P, Todd M, Kuo LC, Rhodes KJ.

J Biol Chem. 2017 Oct 27;292(43):17963-17974. doi: 10.1074/jbc.M117.806075. Epub 2017 Aug 31.

5.

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A.

Nature. 2017 Jun 21;546(7659):564. doi: 10.1038/nature22809.

PMID:
28640269
6.

Dimethyl fumarate improves white matter function following severe hypoperfusion: Involvement of microglia/macrophages and inflammatory mediators.

Fowler JH, McQueen J, Holland PR, Manso Y, Marangoni M, Scott F, Chisholm E, Scannevin RH, Hardingham GE, Horsburgh K.

J Cereb Blood Flow Metab. 2018 Aug;38(8):1354-1370. doi: 10.1177/0271678X17713105. Epub 2017 Jun 13.

7.

The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes.

Brennan MS, Matos MF, Richter KE, Li B, Scannevin RH.

Sci Rep. 2017 Feb 9;7:42054. doi: 10.1038/srep42054.

8.

Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments.

Peng H, Li H, Sheehy A, Cullen P, Allaire N, Scannevin RH.

J Neuroimmunol. 2016 Oct 15;299:35-44. doi: 10.1016/j.jneuroim.2016.08.006. Epub 2016 Aug 5.

PMID:
27725119
9.

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A.

Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. Update in: Nature. 2017 Jun 21;546(7659):564.

PMID:
27582220
10.

Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2.

Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, Cree BA, Sobel RA, Wipke BT, Steinman L, Scannevin RH, Zamvil SS.

Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4777-82. doi: 10.1073/pnas.1603907113. Epub 2016 Apr 13.

11.

Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.

Lastres-Becker I, García-Yagüe AJ, Scannevin RH, Casarejos MJ, Kügler S, Rábano A, Cuadrado A.

Antioxid Redox Signal. 2016 Jul 10;25(2):61-77. doi: 10.1089/ars.2015.6549. Epub 2016 Apr 27.

12.

Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms.

Brennan MS, Patel H, Allaire N, Thai A, Cullen P, Ryan S, Lukashev M, Bista P, Huang R, Rhodes KJ, Scannevin RH.

Antioxid Redox Signal. 2016 Jun 20;24(18):1058-71. doi: 10.1089/ars.2015.6622. Epub 2016 Apr 28.

PMID:
26980071
13.

BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.

Scannevin RH, Chollate S, Brennan MS, Snodgrass-Belt PA, Peng H, Xu L, Jung MY, Bussiere T, Arastu MF, Talreja T, Xin Z, Dunstan RW, Fahrer D, Rohde E, Dunah AW, Wang J, Kumaravel G, Taveras AG, Moore Arnold H, Rhodes KJ.

Neuropharmacology. 2016 Apr;103:57-68. doi: 10.1016/j.neuropharm.2015.12.006. Epub 2015 Dec 12.

PMID:
26690893
14.

DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner.

Gillard GO, Collette B, Anderson J, Chao J, Scannevin RH, Huss DJ, Fontenot JD.

J Neuroimmunol. 2015 Jun 15;283:74-85. doi: 10.1016/j.jneuroim.2015.04.006. Epub 2015 Apr 23.

15.

Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2.

Bell KF, Al-Mubarak B, Martel MA, McKay S, Wheelan N, Hasel P, Márkus NM, Baxter P, Deighton RF, Serio A, Bilican B, Chowdhry S, Meakin PJ, Ashford ML, Wyllie DJ, Scannevin RH, Chandran S, Hayes JD, Hardingham GE.

Nat Commun. 2015 May 13;6:7066. doi: 10.1038/ncomms8066.

16.

Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.

Parodi B, Rossi S, Morando S, Cordano C, Bragoni A, Motta C, Usai C, Wipke BT, Scannevin RH, Mancardi GL, Centonze D, Kerlero de Rosbo N, Uccelli A.

Acta Neuropathol. 2015 Aug;130(2):279-95. doi: 10.1007/s00401-015-1422-3. Epub 2015 Apr 29.

17.

Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.

Brennan MS, Matos MF, Li B, Hronowski X, Gao B, Juhasz P, Rhodes KJ, Scannevin RH.

PLoS One. 2015 Mar 20;10(3):e0120254. doi: 10.1371/journal.pone.0120254. eCollection 2015.

18.

Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation.

Reick C, Ellrichmann G, Thöne J, Scannevin RH, Saft C, Linker RA, Gold R.

Exp Neurol. 2014 Jul;257:50-6. doi: 10.1016/j.expneurol.2014.04.003. Epub 2014 Apr 13.

PMID:
24731948
19.

Synapto-depressive effects of amyloid beta require PICK1.

Alfonso S, Kessels HW, Banos CC, Chan TR, Lin ET, Kumaravel G, Scannevin RH, Rhodes KJ, Huganir R, Guckian KM, Dunah AW, Malinow R.

Eur J Neurosci. 2014 Apr;39(7):1225-33. doi: 10.1111/ejn.12499.

20.

Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.

Sheikh SI, Nestorov I, Russell H, O'Gorman J, Huang R, Milne GL, Scannevin RH, Novas M, Dawson KT.

Clin Ther. 2013 Oct;35(10):1582-1594.e9. doi: 10.1016/j.clinthera.2013.08.009.

21.

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.

Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT.

Curr Med Res Opin. 2014 Feb;30(2):251-62. doi: 10.1185/03007995.2013.849236. Epub 2013 Oct 22. Review.

PMID:
24131282
22.

Substituted thieno[2,3-d]pyrimidines as adenosine A2A receptor antagonists.

Shook BC, Chakravarty D, Barbay JK, Wang A, Leonard K, Alford V, Powell MT, Rassnick S, Scannevin RH, Carroll K, Wallace N, Crooke J, Ault M, Lampron L, Westover L, Rhodes K, Jackson PF.

Bioorg Med Chem Lett. 2013 May 1;23(9):2688-91. doi: 10.1016/j.bmcl.2013.02.078. Epub 2013 Feb 27.

PMID:
23522563
23.

Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway.

Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, Rhodes KJ.

J Pharmacol Exp Ther. 2012 Apr;341(1):274-84. doi: 10.1124/jpet.111.190132. Epub 2012 Jan 20.

PMID:
22267202
24.

Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.

Shook BC, Rassnick S, Wallace N, Crooke J, Ault M, Chakravarty D, Barbay JK, Wang A, Powell MT, Leonard K, Alford V, Scannevin RH, Carroll K, Lampron L, Westover L, Lim HK, Russell R, Branum S, Wells KM, Damon S, Youells S, Li X, Beauchamp DA, Rhodes K, Jackson PF.

J Med Chem. 2012 Feb 9;55(3):1402-17. doi: 10.1021/jm201640m. Epub 2012 Jan 26.

PMID:
22239465
25.

Discovery of 4-aminomethylphenylacetic acids as γ-secretase modulators via a scaffold design approach.

Xin Z, Peng H, Zhang A, Talreja T, Kumaravel G, Xu L, Rohde E, Jung MY, Shackett MN, Kocisko D, Chollate S, Dunah AW, Snodgrass-Belt PA, Arnold HM, Taveras AG, Rhodes KJ, Scannevin RH.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7277-80. doi: 10.1016/j.bmcl.2011.10.047. Epub 2011 Oct 19.

PMID:
22061640
26.

Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator.

Peng H, Talreja T, Xin Z, Cuervo JH, Kumaravel G, Humora MJ, Xu L, Rohde E, Gan L, Jung MY, Shackett MN, Chollate S, Dunah AW, Snodgrass-Belt PA, Arnold HM, Taveras AG, Rhodes KJ, Scannevin RH.

ACS Med Chem Lett. 2011 Aug 5;2(10):786-91. doi: 10.1021/ml200175q. eCollection 2011 Oct 13.

27.

Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.

Wilson LJ, Wang B, Yang SM, Scannevin RH, Burke SL, Karnachi P, Rhodes KJ, Murray WV.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6485-90. doi: 10.1016/j.bmcl.2011.08.068. Epub 2011 Aug 28.

PMID:
21925881
28.

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Brück W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R.

Brain. 2011 Mar;134(Pt 3):678-92. doi: 10.1093/brain/awq386.

PMID:
21354971
29.

Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.

Shook BC, Rassnick S, Hall D, Rupert KC, Heintzelman GR, Hansen K, Chakravarty D, Bullington JL, Scannevin RH, Magliaro B, Westover L, Carroll K, Lampron L, Russell R, Branum S, Wells K, Damon S, Youells S, Li X, Osbourne M, Demarest K, Tang Y, Rhodes K, Jackson PF.

Bioorg Med Chem Lett. 2010 May 1;20(9):2864-7. doi: 10.1016/j.bmcl.2010.03.042. Epub 2010 Mar 11.

PMID:
20347304
30.

Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.

Shook BC, Rassnick S, Chakravarty D, Wallace N, Ault M, Crooke J, Barbay JK, Wang A, Leonard K, Powell MT, Alford V, Hall D, Rupert KC, Heintzelman GR, Hansen K, Bullington JL, Scannevin RH, Carroll K, Lampron L, Westover L, Russell R, Branum S, Wells K, Damon S, Youells S, Beauchamp D, Li X, Rhodes K, Jackson PF.

Bioorg Med Chem Lett. 2010 May 1;20(9):2868-71. doi: 10.1016/j.bmcl.2010.03.024. Epub 2010 Mar 7.

PMID:
20338760
31.

Heat shock protein 90: inhibitors in clinical trials.

Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC.

J Med Chem. 2010 Jan 14;53(1):3-17. doi: 10.1021/jm9004708. No abstract available. Erratum in: J Med Chem. 2010 Mar 11;53(5):2332.

PMID:
20055425
32.

Extension of the thrombolytic time window with minocycline in experimental stroke.

Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH.

Stroke. 2008 Dec;39(12):3372-7. doi: 10.1161/STROKEAHA.108.514026. Epub 2008 Oct 16.

33.

beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.

Yang SM, Scannevin RH, Wang B, Burke SL, Wilson LJ, Karnachi P, Rhodes KJ, Lagu B, Murray WV.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1135-9. Epub 2007 Dec 5.

PMID:
18086526
34.

beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.

Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1140-5. Epub 2007 Dec 5.

PMID:
18083558
35.

1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.

Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):409-13. Epub 2007 Oct 18.

PMID:
17981034
36.

Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).

Zhang YM, Fan X, Yang SM, Scannevin RH, Burke SL, Rhodes KJ, Jackson PF.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):405-8. Epub 2007 Oct 18.

PMID:
17980583
37.

Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators.

Lee SR, Guo SZ, Scannevin RH, Magliaro BC, Rhodes KJ, Wang X, Lo EH.

Neurosci Lett. 2007 Apr 24;417(1):1-5. Epub 2007 Jan 11.

PMID:
17386975
38.

Two N-terminal domains of Kv4 K(+) channels regulate binding to and modulation by KChIP1.

Scannevin RH, Wang K, Jow F, Megules J, Kopsco DC, Edris W, Carroll KC, Lü Q, Xu W, Xu Z, Katz AH, Olland S, Lin L, Taylor M, Stahl M, Malakian K, Somers W, Mosyak L, Bowlby MR, Chanda P, Rhodes KJ.

Neuron. 2004 Feb 19;41(4):587-98.

39.

Identification of a trafficking determinant localized to the Kv1 potassium channel pore.

Manganas LN, Wang Q, Scannevin RH, Antonucci DE, Rhodes KJ, Trimmer JS.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):14055-9. Epub 2001 Nov 6.

40.

Activation of silent synapses by rapid activity-dependent synaptic recruitment of AMPA receptors.

Liao D, Scannevin RH, Huganir R.

J Neurosci. 2001 Aug 15;21(16):6008-17.

41.

Postsynaptic organization and regulation of excitatory synapses.

Scannevin RH, Huganir RL.

Nat Rev Neurosci. 2000 Nov;1(2):133-41. Review.

PMID:
11252776
42.
43.

A novel targeting signal for proximal clustering of the Kv2.1 K+ channel in hippocampal neurons.

Lim ST, Antonucci DE, Scannevin RH, Trimmer JS.

Neuron. 2000 Feb;25(2):385-97.

44.

Phosphorylation of the Kv2.1 K+ channel alters voltage-dependent activation.

Murakoshi H, Shi G, Scannevin RH, Trimmer JS.

Mol Pharmacol. 1997 Nov;52(5):821-8.

PMID:
9351973
45.

Cytoplasmic domains of voltage-sensitive K+ channels involved in mediating protein-protein interactions.

Scannevin RH, Trimmer JS.

Biochem Biophys Res Commun. 1997 Mar 27;232(3):585-9. Review. No abstract available.

PMID:
9126317
46.

Identification of a cytoplasmic domain important in the polarized expression and clustering of the Kv2.1 K+ channel.

Scannevin RH, Murakoshi H, Rhodes KJ, Trimmer JS.

J Cell Biol. 1996 Dec;135(6 Pt 1):1619-32.

Supplemental Content

Loading ...
Support Center